ABOS

Acumen Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth 0/10
  • Value 5/10
Acumen Pharmaceuticals sales and earnings growth
ABOS Growth
Low
  • Revenue Y/Y 0.00%
  • EPS Y/Y 4.12%
  • FCF Y/Y -2.92%
Acumen Pharmaceuticals gross and profit margin trends
ABOS Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y -55.94%
Acumen Pharmaceuticals net debt vs free cash flow
ABOS Risk
Great
  • Debt / Equity 0.4
  • Debt / FCF 0.0
  • Interest coverage -25.5

Acumen Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks